AstraZeneca’s DAISY Study: A New Hope for Systemic Sclerosis Treatment

AstraZeneca ((AZN)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: The DAISY study, officially titled ‘A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared With Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive With Systemic Sclerosis,’ aims to assess the efficacy and safety of anifrolumab in treating systemic sclerosis. This condition, also known as scleroderma, is a chronic connective tissue disease. The study’s significance lies in its potential to offer a new treatment option for patients with limited or diffuse cutaneous subsets of systemic sclerosis. Intervention/Treatment: The study tests anifrolumab, a subcutaneous injection administered weekly. Anifrolumab is designed to treat systemic sclerosis by modulating the immune response, potentially reducing disease symptoms and progression. Study Design: This Phase III study is interventional, with participants randomly allocated to receive either anifrolumab or a placebo in a parallel model. The study is double-blind for the first 52 weeks, meaning neither participants nor researchers know who receives the treatment or placebo. After this period, all participants receive anifrolumab in an open-label phase for another 52 weeks, focusing on treatment efficacy and safety. Study Timeline: The study began on June 2, 2023, and is currently recruiting participants. The primary completion date is set for 2025, with the study’s estimated completion and last update submitted on August 14, 2025. These dates are crucial for tracking the study’s progress and anticipating results. Market Implications: This study update could positively impact AstraZeneca’s stock performance by showcasing the company’s commitment to expanding its treatment portfolio. Successful results may enhance investor sentiment, given the unmet needs in systemic sclerosis treatment. Competitors in the autoimmune disease treatment space will likely monitor these developments closely. The DAISY study is ongoing, with further details available on the ClinicalTrials portal. Trending Articles:Contractors Offer a Look at Things They Won’t Buy at Home Depot (NYSE:HD) Airbus Stock (NASDAQ:EADSY) Slips Following Lower August Delivery Numbers 3 Mega Cap Stocks with Potential to Beat the Market, 9/5/25Disclaimer & DisclosureReport an Issue